Drug Search Results

CPP-115

Alternative Names: cpp-115
Latest Update: 2023-08-22
Latest Update Note: News Article

Product Description

Mechanisms of Action: ABAT Deactivator

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Catalyst
Company Location: SOUTH SAN FRANCISCO CA 94080
Company CEO: Nassim Usman
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for CPP-115

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Cocaine-Related Disorders

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
CPP-115-0001	P1	Completed	Cocaine-Related Disorders	2012-06-01

Recent News Events

Date	Type	Title
08/22/2023	News Article	Akava Therapeutics, Inc. Announces FDA Clearance of Investigational New Drug Application for the Treatment of Amyotrophic Lateral Sclerosis
02/24/2023	PubMed	Identification of novel C-15 fluoro isosteviol derivatives for GABA-AT inhibition by in silico investigations.
01/05/2023	News Article	Ovid Therapeutics Dosed Healthy Volunteers with OV329 in Phase 1 Trial
03/30/2022	PubMed	Rational Design, Synthesis, and Mechanism of (3S,4R)-3-Amino-4-(difluoromethyl)cyclopent-1-ene-1-carboxylic Acid: Employing a Second-Deprotonation Strategy for Selectivity of Human Ornithine Aminotransferase over GABA Aminotransferase.
04/16/2021	PubMed	Theoretical and Mechanistic Validation of Global Kinetic Parameters of the Inactivation of GABA Aminotransferase by OV329 and CPP-115.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions